(MENAFN- ProactiveInvestors)Suzanne Dilly the chief executive officer of ValiSeek a division life sciences firm ValiRx (LON:VAL) explains the company's deal with Clinical Accelerator to carry out the work on a Phase IIB study for lung cancer treatment VAL 401. The drug is being developed through a joint venture with Tangent Profiling to target patients with non-small-cell lung adenocarcinoma the most common form of the disease.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.